The high success rate of PARPi in breast and ovarian cancers might be attributed to a subset of these cases enriched with BRCA1/2 pathogenic variants and a sensitive threshold to distinguish HR deficient and HR proficient tumors [13,14]. The gene discussed is BRCA1; the disease is ovarian carcinoma.